ObjectiveTo retrospective analysis the research progress of the acute-on-chronic liver failure (ACLF), and provide some useful advice for the early diagnosis, evaluation, and treatments of ACLF. MethodsThe literatures on ACLF which published in domestic and overseas for these years were reviewed. ResultsACLF, which is an acute deterioration of liver function results from precipitating events in patients with chronic liver disease. As an independent clinical entity and different from acute liver failure (ALF), sub-acute liver failure (SALF), and chronic liver failure (CLF). For the high short-term mortality and seldom good treatment measures, attached much people's attention. ConclusionThe research of ACLF makes great advance but still exits different in some field between the East and the West. Search dangerous etiology earlier, combine with reality and early effective treatments can develop total survival rate of ACLF.
ObjectiveTo explore the expressions of polo-like kinase 1(PLK1) and serine/threonine kinase 15 (STK15) mRNA and protein in colon cancer cells, and to explore the inhibitive effect of SBE13 and VX-680 for PLK1 protein and STK15 protein. MethodsOne kind of cervical cancer cells(Hela cells) and 3 kinds of colon cancer cells (HCT-116 cells, HT-29 cells, and CACO-2 cells) were selected for experiment. Expression levels of PLK1 mRNA, STK15 mRNA and its protein of 4 kinds of cells were detected by reverse transcription polymerase chain reaction(RT-PCR) and Western blot method respectively. Inhibitive effect of SBE13 and VX-680 were evaluated in vitro by methylthiazolyldiphenyl-tetrazolium bromide(MTT) assay in 4 kinds of cells, which divided into 5 groups, receiving Dulbecco's modification of Eagle's medium(DMEM), dimethylsulfoxide(DMSO), SBE13, VX-680, and SBE13+VX-680 respectively. ResultsCompared with Hela cells, expression levels of PLK1 mRNA, STK15 mRNA and its protein in HCT-116 cells,HT-29 cells, and CACO-2 cells were higher(P<0.05). ① Hela cells:Compared with DMEM group, the proliferative activity were not inhibited in SBE13 group, VX-680 group, and SBE13+VX-680 group(P>0.05). ② HCT-116 cells and HT-29 cells:Compared with DMEM group, the proliferative activity were inhibited in VX-680 group and SBE13+VX-680 group(P<0.05), but was not inhibited in SBE13 group(P>0.05). ③ CACO-2 cell:Compared with DMEM group, the proliferative activity were inhibited in SBE13 group, VX-680 group, and SBE13+VX-680 group(P<0.05). ConclusionsExpression levels of PLK1 mRNA, STK15 mRNA and its protein increase in HCT-116, HT-29, and CACO-2 cells compared with Hela cells. SBE13 and VX-680 can inhibit PLK1 and STK15 protein partly in colon cancer cell lines.
ObjectiveTo evaluate value of percutaneous interventional treatment for portal vein thrombosis combined with occlusion following liver transplantation. Method The data of 3 patients with portal vein thrombosis combined with occlusion following liver transplantation underwent interventional treatment were analyzed retrospectively. Resultsthe mural thrombi were detected preoperatively in the portal venous trunk for the 3 patients, all of which were classified as Yerdel's grade 1 and were underwent porto-portal anastomosis without thrombectomy during liver transplantation. Portal vein thrombosis combined with occlusion occured after 8 months postoperatively. The percutaneous transhepatic balloon venoplasty and self-expanding metallic stents placement was performed in 3 patients. The interventional treatment was successfully achieved in all the patients. The follow-up period ranged from 28 to 38 months, no complications occurred following interventional treatment, the graft function and survival of patients were good. ConclusionPercutaneous interventional treatment is an efficacious and safe method to treat portal vein thrombosis combined with occlusion.